Biotech Pipeline Risk Report

Abstract

The Revere Biotech Pipeline Risk Report includes a list of Biotech companies that meet the following criteria:

• At least two Phase 3/ FDA-filed drug candidates
• One or more drug candidates utilizing a mechanism of action already approved by the FDA
• One or more drug candidates facing two or fewer alternative drugs with the same mechanism of action for the same indication
• An established strategic partnership with one or more blue-chip biopharmaceutical companies
• Market cap between $50 million and $1 billion

Using Revere's patented classification system, this report makes available to investors a portfolio of Biotech stocks that addresses all 3 diversification characteristics that are essential for successful Biotech investing. Also included in the report are each late stage candidate's key upcoming catalyst events, its indications, and its mechanism of actions.